We support the controls of statin prescriptions but urge authorities to eliminate the heavy administrative burden that currently undermines preventive care. We also stress that statin intolerance be diagnosed through clinical symptoms, not just lab tests. Additionally, we call for better reimbursement of lifestyle change programmes.
See our full response (Nl & FR) on the monitoring of reimbursement for lipid-lowering therapy sent to Minister Vandenbroucke, RIZIV/INAMI and mutualities.